Drug
18F-rhPSMA-7.3
18F-rhPSMA-7.3 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_2
1
25%
Ph early_phase_1
1
25%
Ph not_applicable
1
25%
Ph phase_4
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Terminated(1)
Detailed Status
Active, not recruiting1
Not yet recruiting1
Withdrawn1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
active_not_recruiting125%
not_yet_recruiting125%
withdrawn125%
recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
NCT07593079
recruitingnot_applicable
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT07011342
active_not_recruitingphase_4
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
NCT06479187
withdrawnearly_phase_1
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
NCT05707182
Clinical Trials (4)
Showing 4 of 4 trials
NCT07593079Phase 2
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
NCT07011342Not Applicable
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
NCT06479187Phase 4
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
NCT05707182Early Phase 1
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4